马来酸罗格列酮对早期糖尿病肾病患者尿白蛋白排泄的影响

目的观察马来酸罗格列酮治疗对伴早期肾病2型糖尿病患者尿白蛋白排泄(UAE)的影响。方法将102例早期糖尿病肾病患者随机分为两组:一组给予马来酸罗格列酮4mg/d,另一组给予二甲双胍750mg/d治疗,疗程12周。比较两组治疗前后UAE、糖脂代谢、胰岛素抵抗及血清炎症标志的变化。结果两组空腹血糖、餐后2h血糖、糖化血红蛋白、空腹胰岛素、胰岛素抵抗指数治疗前后比较,差别有统计学意义(P<0.05)。罗格列酮组治疗后UAE、甘油三酯和高敏C反应蛋白下降,高密度脂蛋白胆固醇升高,与治疗前比较,差别有统计学意义(P<0.05)。两组总胆固醇和低密度脂蛋白胆固醇治疗前后比较,差别无统计学意义(P>0.05)。结论罗格列酮能有效降低糖尿病肾病患者的尿蛋白,因此可能对糖尿病血管病变具有临床益处。

Effects of Rosiglitazone on Urinary Albumin Excretion in Patients with Early Diabetic Nephropathy

Objective To evaluate the effects of rosiglitazone therapy on urinary albumin excretion(UAE)in patients with early diabetic nephropathy(EDN).Methods 102 EDN patients were randomly allocated into two groups to be treated for 12 weeks with rosiglitazone 4 mg or with metformin 750 mg daily to compare the UAE,glucose & lipids levels,insulin resistance(IR)and serum inflammation markers before and after treatment.Results Levels of FPG,2 hPG,HbA1c,FIns and HOMA-IR were decreased similarly in two groups after treatment.Rosiglitazone reduced UAE,TG and hsC-RP,increased HDL-C significantly(P<0.05),the levels of TC and LDL-C were not significantly changed after treatment(P>0.05).Conclusions Rosiglitazone could effectively decrease urinary protein excretion in EDN patients;therefore it might be useful in the treatment of diabetic angiopathy.